At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
AZD2281drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
In Brief
A Phase 2 clinical trial evaluating AZD2281 for Ovarian Carcinoma and Breast Cancer. Completed, enrolled 99 participants across 6 sites.
Detailed Summary
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to assess for early markers of activity and to assess correlative markers that may provide helpful information for subsequent clinical trials. Approximately 110 patients from 7 centers in Canada will be enrolled into this study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Carcinoma, Breast Cancer
CountriesCanada
CollaboratorsBritish Columbia Cancer Agency
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJul 2008
Primary CompletionMar 2010
Study CompletionJul 2022
TodayJul 2026
First PostedMay 19, 2008
Enrollment StartJul 8, 2008
Primary CompletionMar 26, 2010
Study CompletionJul 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.1 years ago
Interventions
AZD2281drug
PARP inhibitor Olaparib tablets, oral